Enanta Pharmaceuticals, Inc (ENTA) Stock Price

ENTAStock

$14.08+59.68%52W

Market Cap$410.09M

P/E—

PEG Ratio—

Div yield—

Beta0.96

ENTA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-9.73%

Price vs S&P 500 (4W)8.76%

VGM Score44.44

Book Value / Share (Quarterly)$3.47

P/TBV (Annual)0.97x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-8.83%

Cash Flow / Share (Quarterly)$-1.27

Price vs S&P 500 (YTD)-22.55%

Net Profit Margin (TTM)-96.89%

EPS (TTM)$-2.41

10-Day Avg Trading Volume0.23M

EPS Excl Extra (TTM)$-2.41

Revenue Growth (5Y)-11.82%

EPS (Annual)$-3.84

ROI (Annual)-39.39%

Net Profit Margin (5Y Avg)-137.71%

Cash / Share (Quarterly)$6.51

Revenue Growth QoQ (YoY)-21.60%

ROA (Last FY)-29.17%

Revenue Growth TTM (YoY)0.70%

EBITD / Share (TTM)$-1.99

ROE (5Y Avg)-67.21%

Operating Margin (TTM)-89.99%

Cash Flow / Share (Annual)$-1.50

P/B Ratio3.87x

P/B Ratio (Quarterly)4.19x

Net Income / Employee (Annual)$-682,400

EV / Revenue (TTM)7.42x

Net Interest Coverage (TTM)12.65x

ROA (TTM)-20.70%

EV / EBITDA (TTM)32.77x

EPS Incl Extra (Annual)$-3.84

Current Ratio (Annual)4.21x

Quick Ratio (Quarterly)3.62x

3-Month Avg Trading Volume0.20M

52-Week Price Return59.68%

Revenue / Employee (TTM)$543,800

Tangible BV / Share (Quarterly)$10.29

P/S Ratio (Annual)5.99x

Asset Turnover (Annual)0.23x

52-Week High$17.15

Operating Margin (5Y Avg)-148.06%

EPS Excl Extra (Annual)$-3.84

CapEx CAGR (5Y)54.82%

Tangible BV CAGR (5Y)-11.25%

26-Week Price Return1.51%

Quick Ratio (Annual)4.03x

13-Week Price Return1.95%

Total Debt / Equity (Annual)2.21x

Current Ratio (Quarterly)3.76x

Enterprise Value$484.41M

Revenue / Share Growth (5Y)-13.04%

Asset Turnover (TTM)0.21x

Book Value / Share Growth (5Y)-33.15%

Revenue / Employee (Annual)$544,400

Pretax Margin (Annual)-127.90%

Cash / Share (Annual)$8.83

3-Month Return Std Dev47.45%

Net Income / Employee (TTM)$-526,900

ROE (Last FY)-126.53%

Net Interest Coverage (Annual)-13.33x

EPS Basic Excl Extra (Annual)$-3.84

P/FCF (TTM)22.56x

Receivables Turnover (TTM)8.78x

Total Debt / Equity (Quarterly)1.25x

EPS Incl Extra (TTM)$-2.41

Receivables Turnover (Annual)9.66x

ROI (TTM)-26.77%

P/S Ratio (TTM)6.00x

Pretax Margin (5Y Avg)-144.00%

Revenue / Share (Annual)$3.06

Tangible BV / Share (Annual)$10.29

Price vs S&P 500 (52W)41.37%

Year-to-Date Return-10.59%

5-Day Price Return6.01%

EPS Normalized (Annual)$-3.84

ROA (5Y Avg)-27.87%

Net Profit Margin (Annual)-125.36%

Month-to-Date Return11.90%

Cash Flow / Share (TTM)$-6.26

EBITD / Share (Annual)$-3.79

Operating Margin (Annual)-130.65%

LT Debt / Equity (Annual)1.74x

ROI (5Y Avg)-39.39%

LT Debt / Equity (Quarterly)0.89x

EPS Basic Excl Extra (TTM)$-2.41

P/TBV (Quarterly)0.97x

P/B Ratio (Annual)3.95x

Pretax Margin (TTM)-96.74%

Book Value / Share (Annual)$3.03

Price vs S&P 500 (13W)-0.84%

Beta0.96x

P/FCF (Annual)69.41x

Revenue / Share (TTM)$2.24

ROE (TTM)-61.84%

52-Week Low$7.05

vGradeC

gGradeD

mGradeB

vgmGradeC

ENTA Earnings Surprise History

Q2 25-0.85est. -0.89

Q3 25-0.87est. -1.01

Q4 25-0.42est. -0.88

Q1 26-0.45est. -0.57

Q2 26-0.67est. -0.51

ENTA Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

4.15

4.25

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
ENTAEnanta Pharmaceuticals, Inc	C	D	B	$14.08
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Enanta Pharmaceuticals, Inc

Enanta Pharmaceuticals is a biotechnology company specializing in small-molecule drug discovery for virology and immunology. Its pipeline includes candidates for RSV, SARS-CoV-2, hepatitis B, and type 2 inflammatory disease. The company generates revenue primarily through royalties, including from its collaboration with AbbVie.